Shares of Catalyst Biosciences (NASDAQ: CBIO) are 15% higher this morning on news that a positive opinion recommending orphan medicinal product designation has been issued by the European Medicines Agency Committee (EMA) for Orphan Medicinal Products (COMP) regarding Catalyst’s CB 2679d for the treatment of hemophilia B. The clinical-stage biopharmaceutical company’s highly potent next-generation coagulation Factor IX variant demonstrated potential to normalize human Factor IX levels with a daily subcutaneous injection in preclinical studies. Currently approved therapies rely on numerous intravenous infusions. “Obtaining orphan drug designation is an important part of our regulatory approval strategy for CB 2679d, and the receipt of the positive COMP opinion puts us one step closer to this goal,” Catalyst president and CEO Nassim Usman, Ph.D. stated in the news release.
To view the full press release, visit: http://nnw.fm/1iAwB
About Catalyst Biosciences, Inc.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, visit www.catalystbiosciences.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
